ALNY vs PVLA
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
Side-by-side fundamentals
| Metric | ALNY | PVLA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $278.40 | $141.77 | |
| Market cap as of 2026-07-31 | $36.9B | $2.0B | |
| P/E as of 2026-07-31 | 50.14 | n/a | |
| PEG as of 2026-07-31 | 1.11 | n/a | |
| Net margin as of 2026-07-31 | +13.5% | -39.7% | ALNY higher |
| Gross margin as of 2026-07-31 | +80.8% | n/a | |
| Operating margin as of 2026-07-31 | +16.6% | -47.8% | ALNY higher |
| ROE as of 2026-07-31 | +98.3% | -56.9% | ALNY higher |
| ROA as of 2026-07-31 | +11.8% | -42.5% | ALNY higher |
| Debt / equity as of 2026-07-31 | 2.52 | 0.09 | PVLA lower |
| Revenue growth (YoY) as of 2026-07-31 | +82.6% | -97.2% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +13.4% | ALNY higher |
| Beta as of 2026-07-31 | 0.28 | -0.20 | |
| 1-year return as of 2026-07-27 close | -15.3% | +267.1% | PVLA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.